Trevi Therapeutics, Inc. (TRVI) stock
TRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.29−0.36 (-2.64%)
Close on Nov 16, 2026Market cap $1.89BP/E –Yield –
Trevi Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Trevi Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $41.37M, up 9.6% year over year. For fiscal 2025 it was $33.48M, down 15.0% from the year before. The highest annual figure on record is $39.38M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.48M | -15.0% |
| FY2024 | Dec 31, 2024 | $39.38M | +66.3% |
| FY2023 | Dec 31, 2023 | $23.68M | +19.4% |
| FY2022 | Dec 31, 2022 | $19.83M | -13.7% |
| FY2021 | Dec 31, 2021 | $22.98M | +2.9% |
| FY2020 | Dec 31, 2020 | $22.33M | +15.5% |
| FY2019 | Dec 31, 2019 | $19.34M | +37.4% |
| FY2018 | Dec 31, 2018 | $14.07M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $15.15M | +61.4% |
| Q1 FY2026 | Mar 31, 2026 | $9.94M | +27.3% |
| Q4 FY2025 | Dec 31, 2025 | $6.19M | -33.6% |
| Q3 FY2025 | Sep 30, 2025 | $10.09M | -10.1% |
| Q2 FY2025 | Jun 30, 2025 | $9.39M | -6.3% |
| Q1 FY2025 | Mar 31, 2025 | $7.81M | -11.3% |
| Q4 FY2024 | Dec 31, 2024 | $9.33M | +43.1% |
| Q3 FY2024 | Sep 30, 2024 | $11.22M | +77.5% |
| Q2 FY2024 | Jun 30, 2024 | $10.02M | +71.5% |
| Q1 FY2024 | Mar 31, 2024 | $8.80M | +76.1% |
| Q4 FY2023 | Dec 31, 2023 | $6.52M | +51.0% |
| Q3 FY2023 | Sep 30, 2023 | $6.32M | +9.6% |
| Q2 FY2023 | Jun 30, 2023 | $5.84M | +14.5% |
| Q1 FY2023 | Mar 31, 2023 | $5.00M | +7.6% |
| Q4 FY2022 | Dec 31, 2022 | $4.32M | -30.1% |
| Q3 FY2022 | Sep 30, 2022 | $5.77M | +22.3% |
| Q2 FY2022 | Jun 30, 2022 | $5.10M | -21.5% |
| Q1 FY2022 | Mar 31, 2022 | $4.65M | -16.9% |
| Q4 FY2021 | Dec 31, 2021 | $6.18M | -5.8% |
| Q3 FY2021 | Sep 30, 2021 | $4.72M | -2.3% |
| Q2 FY2021 | Jun 30, 2021 | $6.50M | +32.0% |
| Q1 FY2021 | Mar 31, 2021 | $5.59M | -7.1% |
| Q4 FY2020 | Dec 31, 2020 | $6.56M | +36.0% |
| Q3 FY2020 | Sep 30, 2020 | $4.83M | -14.5% |
| Q2 FY2020 | Jun 30, 2020 | $4.92M | -11.0% |
| Q1 FY2020 | Mar 31, 2020 | $6.02M | +80.3% |
| Q4 FY2019 | Dec 31, 2019 | $4.82M | +6.6% |
| Q3 FY2019 | Sep 30, 2019 | $5.65M | +50.8% |
| Q2 FY2019 | Jun 30, 2019 | $5.53M | +60.7% |
| Q1 FY2019 | Mar 31, 2019 | $3.34M | +41.3% |
| Q4 FY2018 | Dec 31, 2018 | $4.52M | – |
| Q3 FY2018 | Sep 30, 2018 | $3.75M | – |
| Q2 FY2018 | Jun 30, 2018 | $3.44M | – |
| Q1 FY2018 | Mar 31, 2018 | $2.36M | – |
See a number that looks wrong?